Fort Lauderdale, FL and Qufu, China, April 5, 2006 (Market Wire ) - Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and low calorie natural sweetener in China, announced continued increases in sales of Hypericin based products.In November 2005, Sunwin launched a marketing effort for two products employing Hypericin as a main component to deter the spread of the avian flu.Since the launch of the marketing efforts, the combined sales of both products increased from 342,300 RMB per month in November 2005 to 685,800 RMB per month in February 2006.

Hypericin is a derivative of St. Johns Wort, which is an English word for a Chinese herb manufactured by Sunwin since 1997.In recent laboratory tests, Hypericin has proven effective as a treatment for poultry infected with strands of the avian flu. The in vitro experiments, performed jointly by the SouthChinaAgriculturalUniversity and the ChineseAcademy of Agricultural Sciences, indicated that when H5N1 and H9N2 avian flu viruses were treated with Hypericin at 3.72 mg/ml for 30 minutes, Hypericin was treating 100% of the viruses. Furthermore, when these viruses were treated with Hypericin at 0.744 mg/ml for 10 minutes, Hypericin was successful in treating over 99.99% of the viruses.

Sunwin coordinated on a joint project with scientists from the e Traditional Chinese Medicine department of ShangdongUniversity, the results were two products which could suppress the spread of certain strands of the avian flu.The two products are marketed to the veterinary community in China as a food additive.The products are mixed with water to feed poultry as a preventative measure to assist in the efforts to prevent the spread of the avian flu.

In November, 2005 Sunwin announced the Department of Livestock Farming for Shandong Province Government submitted a fast-track application to the Livestock Farming Bureau of China Ministry of Agriculture for approval of Hypericin related products as a class one new veterinary medicine to treat strands of the avian flu virus.While the China Ministry of Agriculture has not provided such clearance as a class one application Sunwin can distribute as a veterinary feed additive within China.

Laiwang Zhang, President and Chairman of Sunwin International Neutraceuticals, Inc., stated, "As we await ruling on Hypericin as a class one veterinary medical application, we launched our two products for sale as a regular veterinary feed additive.The preliminary response has been favorable, and we continue to witness steady growth in sales of these two products. "

About Sunwin International Neutraceuticals, Inc.

Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN) is engaged in the areas of essential traditional Chinese medicine, low-calorie natural sweetener (Stevia), and veterinary medicines and feeds prepared from 100% organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumer to provide a quality and a hybrid mix of agricultural products and services that meet growing demand. For more info about Sunwin, please visit http://www.sunwin.biz

Safe Harbor Statement

Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Reported results should not be considered as an indication of future performance. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:

Tel: 1-877-CHINA-57
Email: info@sunwin.biz